Avgerinos I, Papanastasiou G, Karagiannis T, et al. - A systematic review and meta-analysis of randomized controlled trials were conducted to evaluate the effectiveness and safety of the novel, ultra-rapid-acting insulins aspart and lispro in adults with type 1 or type 2 diabetes. Researchers estimated weighted mean differences for continuous outcomes and odds ratios for dichotomous outcomes, alongside 95% confidence intervals. They further evaluated statistical heterogeneity among studies with the I ² statistic, considering values greater than 60% as indicative of substantial heterogeneity. The research enrolled nine studies comprising 5,931 patients in the systematic review; eight active-controlled studies could be synthesized in terms of a meta-analysis. The results showed that ultra-rapid-acting insulins were as efficacious and safe as rapid-acting insulins, demonstrating a favourable effect solely on PPG control.